CN1020944C
(zh)
*
|
1990-01-30 |
1993-05-26 |
阿图尔-费希尔股份公司费希尔厂 |
紧固件
|
US6515117B2
(en)
*
|
1999-10-12 |
2003-02-04 |
Bristol-Myers Squibb Company |
C-aryl glucoside SGLT2 inhibitors and method
|
FR2809310B1
(fr)
*
|
2000-05-26 |
2004-02-13 |
Centre Nat Rech Scient |
Utilisation de derives de biguanide pour fabriquer un medicament ayant un effet cicatrisant
|
EP1345602B1
(en)
|
2000-11-30 |
2010-07-21 |
Novodermix International Limited |
Wound healing
|
HU230382B1
(hu)
*
|
2001-02-24 |
2016-03-29 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Xantinszármazékok, előállításuk és alkalmazásuk gyógyszerként
|
US6936590B2
(en)
*
|
2001-03-13 |
2005-08-30 |
Bristol Myers Squibb Company |
C-aryl glucoside SGLT2 inhibitors and method
|
JP4590159B2
(ja)
*
|
2001-04-04 |
2010-12-01 |
オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド |
グルコース再吸収阻害剤およびpparモジュレーターを含んで成る併用療法
|
EP1385856B1
(en)
*
|
2001-04-11 |
2006-02-22 |
Bristol-Myers Squibb Company |
Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
|
WO2003020737A1
(en)
*
|
2001-09-05 |
2003-03-13 |
Bristol-Myers Squibb Company |
O-pyrazole glucoside sglt2 inhibitors and method of use
|
TWI254635B
(en)
*
|
2002-08-05 |
2006-05-11 |
Yamanouchi Pharma Co Ltd |
Azulene derivative and salt thereof
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
CA2500873C
(en)
|
2002-10-04 |
2012-01-17 |
Kissei Pharmaceutical Co., Ltd. |
Pyrazole derivative, medicinal composition containing the same, medicinal use thereof and intermediate in producing the same
|
DE10258007B4
(de)
*
|
2002-12-12 |
2006-02-09 |
Sanofi-Aventis Deutschland Gmbh |
Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
EP1581543A4
(en)
*
|
2003-01-03 |
2008-03-19 |
Bristol Myers Squibb Co |
METHODS FOR PRODUCING SGLT2 GLYCOSIS C-ARYL INHIBITORS
|
EP1457206A1
(en)
*
|
2003-03-13 |
2004-09-15 |
Fournier Laboratories Ireland Limited |
Combined use of a fibrate and orlistat for the treatment of obesity
|
TWI310033B
(en)
|
2003-03-14 |
2009-05-21 |
Yamanouchi Pharma Co Ltd |
C-glycoside derivatives or salts thereof
|
JP2004300102A
(ja)
*
|
2003-03-31 |
2004-10-28 |
Kissei Pharmaceut Co Ltd |
縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
|
US8785403B2
(en)
|
2003-08-01 |
2014-07-22 |
Mitsubishi Tanabe Pharma Corporation |
Glucopyranoside compound
|
RS20060320A
(en)
*
|
2003-08-01 |
2008-08-07 |
Janssen Pharmaceutica N.V., |
Substituted indazole-o-glucosides
|
CA2549025A1
(en)
*
|
2003-08-01 |
2005-02-10 |
Janssen Pharmaceutica N.V. |
Substituted indole-o-glucosides
|
CA2549022A1
(en)
*
|
2003-08-01 |
2005-02-10 |
Janssen Pharmaceutica N.V. |
Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides
|
SI1651658T2
(sl)
*
|
2003-08-01 |
2020-12-31 |
Mitsubishi Tanabe Pharma Corporation |
Nove spojine, ki imajo inhibitorno aktivnost proti transporterju, ki je odvisen od natrija
|
WO2005012318A2
(en)
*
|
2003-08-01 |
2005-02-10 |
Janssen Pharmaceutica Nv |
Substituted fused heterocyclic c-glycosides
|
US7371759B2
(en)
*
|
2003-09-25 |
2008-05-13 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
US7420059B2
(en)
*
|
2003-11-20 |
2008-09-02 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
WO2005085265A1
(ja)
*
|
2004-03-04 |
2005-09-15 |
Kissei Pharmaceutical Co., Ltd. |
縮合ヘテロ環誘導体、それを含有する医薬組成物およびその医薬用途
|
SG151271A1
(en)
|
2004-03-16 |
2009-04-30 |
Boehringer Ingelheim Int |
Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof
|
PL1750862T3
(pl)
*
|
2004-06-04 |
2011-06-30 |
Teva Pharma |
Kompozycja farmaceutyczna zawierająca irbesartan
|
US7393836B2
(en)
|
2004-07-06 |
2008-07-01 |
Boehringer Ingelheim International Gmbh |
D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
|
US7572805B2
(en)
|
2004-07-14 |
2009-08-11 |
Bristol-Myers Squibb Company |
Pyrrolo(oxo)isoquinolines as 5HT ligands
|
DE102004034690A1
(de)
*
|
2004-07-17 |
2006-02-02 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
TW200606129A
(en)
*
|
2004-07-26 |
2006-02-16 |
Chugai Pharmaceutical Co Ltd |
Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
|
CA2574451A1
(en)
*
|
2004-07-27 |
2006-02-02 |
Boehringer Ingelheim International Gmbh |
D-glucopyranosyl phenyl-substituted cyclene, medicaments containing these compounds, their use, and method for the production thereof
|
AR051446A1
(es)
*
|
2004-09-23 |
2007-01-17 |
Bristol Myers Squibb Co |
Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
|
EP1803729A4
(en)
*
|
2004-09-29 |
2008-10-01 |
Kissei Pharmaceutical |
HETEROCYCLIC NITROGENIC COMPOUND 1- (-D-GLYCOPYRANOSYL) -3-SUBSTITUTED, THERAPEUTIC PREPARATION CONTAINING SAID COMPOUND, AND MEDICAL USE OF SAID COMPOUND
|
DE102004048388A1
(de)
|
2004-10-01 |
2006-04-06 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
EP1807093A2
(en)
*
|
2004-10-13 |
2007-07-18 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of ptp1b expression
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
EP1828216B1
(en)
*
|
2004-12-16 |
2008-09-10 |
Boehringer Ingelheim International GmbH |
Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
TW200637869A
(en)
|
2005-01-28 |
2006-11-01 |
Chugai Pharmaceutical Co Ltd |
The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
|
AR053329A1
(es)
*
|
2005-01-31 |
2007-05-02 |
Tanabe Seiyaku Co |
Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
|
MY147375A
(en)
*
|
2005-01-31 |
2012-11-30 |
Mitsubishi Tanabe Pharma Corp |
Indole derivatives
|
WO2006086464A2
(en)
*
|
2005-02-10 |
2006-08-17 |
Bristol-Myers Squibb Company |
Dihydroquinazolinones as 5ht modulators
|
JP5264183B2
(ja)
*
|
2005-02-23 |
2013-08-14 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
グルコピラノシル置換((ヘテロ)アリールエチニル−ベンジル)−ベンゼン誘導体及びナトリウム依存性グルコース共輸送体2(sglt2)インヒビターとしてのそれらの使用
|
CA2605245A1
(en)
*
|
2005-04-15 |
2006-10-19 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives as sglt inhibitors
|
US7723309B2
(en)
*
|
2005-05-03 |
2010-05-25 |
Boehringer Ingelheim International Gmbh |
Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
|
UA91546C2
(uk)
*
|
2005-05-03 |
2010-08-10 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
|
US7772191B2
(en)
*
|
2005-05-10 |
2010-08-10 |
Boehringer Ingelheim International Gmbh |
Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
|
WO2007000445A1
(en)
*
|
2005-06-29 |
2007-01-04 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
TW200726755A
(en)
*
|
2005-07-07 |
2007-07-16 |
Astellas Pharma Inc |
A crystalline choline salt of an azulene derivative
|
JP5128474B2
(ja)
*
|
2005-07-27 |
2013-01-23 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
グルコピラノシル−置換((ヘテロ)シクロアルキルエチニル−ベンジル)−ベンゼン誘導体、該化合物を含有する薬剤、それらの使用及びそれらの製造方法
|
JP2009502959A
(ja)
*
|
2005-07-28 |
2009-01-29 |
ブリストル−マイヤーズ スクイブ カンパニー |
セロトニン受容体アゴニストおよびアンタゴニストとしての置換テトラヒドロ−1h−ピリド[4,3,b]インドール
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
US7795436B2
(en)
*
|
2005-08-24 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
|
DE602006017566D1
(de)
*
|
2005-08-30 |
2010-11-25 |
Boehringer Ingelheim Pharma |
Glucopyranosyl-substituierte benzyl-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
|
JP5345846B2
(ja)
*
|
2005-09-08 |
2013-11-20 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
1−クロロ−4−(β−D−グルコピラノス−1−イル)−2−(4−エチニル−ベンジル)−ベンゼンの結晶形態、その製造方法及び薬剤製造のためのそれらの使用
|
AR056195A1
(es)
*
|
2005-09-15 |
2007-09-26 |
Boehringer Ingelheim Int |
Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
|
RU2438671C2
(ru)
*
|
2005-12-28 |
2012-01-10 |
Такеда Фармасьютикал Компани Лимитед |
Терапевтическое средство против диабета
|
EP1989191B1
(en)
|
2006-02-15 |
2011-07-20 |
Boehringer Ingelheim International GmbH |
Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
|
PE20080697A1
(es)
*
|
2006-05-03 |
2008-08-05 |
Boehringer Ingelheim Int |
Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
|
NZ619413A
(en)
|
2006-05-04 |
2015-08-28 |
Boehringer Ingelheim Int |
Polymorphs of a dpp-iv enzyme inhibitor
|
PE20110235A1
(es)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
WO2007143052A1
(en)
*
|
2006-06-01 |
2007-12-13 |
Glycomimetics, Inc. |
Galactosides and thiodigalactosides as inhibitors of pa-il lectin from pseudomonas
|
DE102006028862A1
(de)
|
2006-06-23 |
2007-12-27 |
Merck Patent Gmbh |
3-Amino-imidazo[1,2-a]pyridinderivate
|
US7919598B2
(en)
|
2006-06-28 |
2011-04-05 |
Bristol-Myers Squibb Company |
Crystal structures of SGLT2 inhibitors and processes for preparing same
|
US7795291B2
(en)
|
2006-07-07 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
|
TWI432446B
(zh)
|
2006-07-27 |
2014-04-01 |
Chugai Pharmaceutical Co Ltd |
稠環螺酮縮醇衍生物、及其做為糖尿病治療藥之使用
|
TWI418556B
(zh)
*
|
2006-07-27 |
2013-12-11 |
Mitsubishi Tanabe Pharma Corp |
吲哚衍生物
|
TWI403516B
(zh)
|
2006-07-27 |
2013-08-01 |
Chugai Pharmaceutical Co Ltd |
To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes
|
CA2656847A1
(en)
|
2006-08-15 |
2008-02-21 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
|
PL2097102T3
(pl)
*
|
2006-09-07 |
2012-10-31 |
Glaxosmithkline Biologicals Sa |
Szczepionka skojarzona o zmniejszonej ilości antygenu wirusa polio
|
TWI499414B
(zh)
|
2006-09-29 |
2015-09-11 |
Lexicon Pharmaceuticals Inc |
鈉與葡萄糖第2型共同運輸體(co-transporter 2)的抑制物與其應用方法
|
US20080194575A1
(en)
*
|
2006-10-04 |
2008-08-14 |
Naiara Beraza |
Treatment for non-alcoholic-steatohepatitis
|
JPWO2008044762A1
(ja)
*
|
2006-10-13 |
2010-02-18 |
中外製薬株式会社 |
チオグルコーススピロケタール誘導体、およびその糖尿病治療薬としての使用
|
EP2086991A1
(en)
|
2006-10-27 |
2009-08-12 |
Boehringer Ingelheim International GmbH |
CRYSTALLINE FORM OF 4-(ß-D-GLUCOPYRANOS-1-YL)-1-METHYL-2-[4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYL]-BENZENE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS
|
WO2008070609A1
(en)
*
|
2006-12-04 |
2008-06-12 |
Janssen Pharmaceutica N.V. |
Thienyl-containing glycopyranosyl derivatives as antidiabetics
|
UY30730A1
(es)
*
|
2006-12-04 |
2008-07-03 |
Mitsubishi Tanabe Pharma Corp |
Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
|
KR20090097184A
(ko)
|
2006-12-06 |
2009-09-15 |
스미스클라인 비참 코포레이션 |
비시클릭 화합물 및 항당뇨병제로서의 용도
|
EP2105442A4
(en)
*
|
2006-12-21 |
2013-01-23 |
Astellas Pharma Inc |
PROCESS FOR PREPARING A C-GLYCOSIDE DERIVATIVE AND SYNTHETIC INTERMEDIATE PRODUCT THEREFOR
|
DE102007008420A1
(de)
|
2007-02-21 |
2008-08-28 |
Merck Patent Gmbh |
Benzimidazolderivate
|
WO2008109591A1
(en)
*
|
2007-03-08 |
2008-09-12 |
Lexicon Pharmaceuticals, Inc. |
Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
|
AR065809A1
(es)
*
|
2007-03-22 |
2009-07-01 |
Bristol Myers Squibb Co |
Formulaciones farmaceuticas que contienen un inhibidor sglt2
|
TW200904454A
(en)
*
|
2007-03-22 |
2009-02-01 |
Bristol Myers Squibb Co |
Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
|
AU2014201239B2
(en)
*
|
2007-03-22 |
2016-03-10 |
Astrazeneca Ab |
Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate
|
PE20090696A1
(es)
*
|
2007-04-20 |
2009-06-20 |
Bristol Myers Squibb Co |
Formas cristalinas de saxagliptina y procesos para preparar las mismas
|
US20100120694A1
(en)
|
2008-06-04 |
2010-05-13 |
Synergy Pharmaceuticals, Inc. |
Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
US7879802B2
(en)
|
2007-06-04 |
2011-02-01 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
CA2694029C
(en)
*
|
2007-07-26 |
2016-10-04 |
Lexicon Pharmaceuticals, Inc. |
Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors
|
CL2008002425A1
(es)
*
|
2007-08-16 |
2009-09-11 |
Boehringer Ingelheim Int |
Composición farmacéutica que comprende un inhibidor de sglt2 y 1-(4-metil-quinazolin-2-il)metil-3metil-7-(-2-butin-1-il)-8-(3-(r)-amino-piperidin-1il)-xantina, un inhibidor de dpp iv y su uso para el tratamiento de la obesidad y de la diabetes tipo 1 y 2 y complicaciones de esta.
|
CL2008002427A1
(es)
*
|
2007-08-16 |
2009-09-11 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
|
ES2733348T3
(es)
*
|
2007-08-17 |
2019-11-28 |
Boehringer Ingelheim Int |
Derivados de purina para uso en el tratamiento de enfermedades relacionadas con FAP
|
JP4809931B2
(ja)
*
|
2007-08-23 |
2011-11-09 |
セラコス・インコーポレイテッド |
ベンジルベンゼン誘導体およびその使用方法
|
UA105480C2
(uk)
*
|
2007-09-10 |
2014-05-26 |
Янссен Фармацевтика Н.В. |
Спосіб одержання сполук, які застосовують як інгібітори натрійзалежного переносника глюкози
|
DE102007048716A1
(de)
|
2007-10-11 |
2009-04-23 |
Merck Patent Gmbh |
Imidazo[1,2-a]pyrimidinderivate
|
PE20091211A1
(es)
*
|
2007-11-30 |
2009-09-14 |
Boehringer Ingelheim Int |
Derivados de pirazolopirimidina como moduladores de pde9a
|
UA101004C2
(en)
|
2007-12-13 |
2013-02-25 |
Теракос, Инк. |
Derivatives of benzylphenylcyclohexane and use thereof
|
CN104387354A
(zh)
*
|
2007-12-27 |
2015-03-04 |
阿斯利康公司 |
Sglt2 抑制剂的晶体结构及其制备方法
|
CL2008003653A1
(es)
|
2008-01-17 |
2010-03-05 |
Mitsubishi Tanabe Pharma Corp |
Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
|
CN101969944B
(zh)
*
|
2008-01-31 |
2013-04-10 |
安斯泰来制药有限公司 |
脂肪性肝病的治疗用医药组合物
|
CN101503399B
(zh)
*
|
2008-02-04 |
2012-06-27 |
白鹭医药技术(上海)有限公司 |
C-芳基葡萄糖苷sglt2抑制剂
|
UA105362C2
(en)
|
2008-04-02 |
2014-05-12 |
Бьорингер Ингельхайм Интернациональ Гмбх |
1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
|
AR071175A1
(es)
*
|
2008-04-03 |
2010-06-02 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
|
DE102008017590A1
(de)
|
2008-04-07 |
2009-10-08 |
Merck Patent Gmbh |
Glucopyranosidderivate
|
US8603989B2
(en)
*
|
2008-05-22 |
2013-12-10 |
Bristol-Myers Squibb Company |
Method for treating and preventing kidney stones employing an SGLT2 inhibitor and composition containing same
|
US8518895B2
(en)
|
2008-05-22 |
2013-08-27 |
Bristol-Myers Squibb Company |
Method for treating hyponatremia employing an SGLT2 inhibitor and composition containing same
|
MX2010012656A
(es)
|
2008-05-22 |
2010-12-20 |
Squibb Bristol Myers Co |
Metodo para tratar la hiperuricemia empleando un inhibidor de sglt2 y composicion que contiene el mismo.
|
PE20100156A1
(es)
*
|
2008-06-03 |
2010-02-23 |
Boehringer Ingelheim Int |
Tratamiento de nafld
|
BRPI0916769A2
(pt)
*
|
2008-07-15 |
2017-09-26 |
Theracos Inc |
derivados de benzilbenzeno deuterados e métodos de uso
|
EP2321341B1
(en)
|
2008-07-16 |
2017-02-22 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
KR20190016601A
(ko)
|
2008-08-06 |
2019-02-18 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
CA2735562C
(en)
*
|
2008-08-15 |
2017-10-17 |
Boehringer Ingelheim International Gmbh |
Dpp-4 inhibitors for wound healing
|
PL2324002T3
(pl)
*
|
2008-08-22 |
2017-03-31 |
Theracos Sub, Llc |
Sposoby otrzymywania inhibitorów sglt2
|
PE20110288A1
(es)
*
|
2008-08-28 |
2011-05-26 |
Pfizer |
Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
|
PE20110383A1
(es)
|
2008-09-08 |
2011-07-15 |
Boehringer Ingelheim Int |
Pirazolopirimidinonas como inhibidores de la fosfodiesterasa 9a (pde9a)
|
RU2011113823A
(ru)
|
2008-09-10 |
2012-10-20 |
БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) |
Комбинированная терапия, предназначенная для лечения диабета и связанных с ним состояний
|
EA201100502A1
(ru)
*
|
2008-09-19 |
2011-10-31 |
Новартис Аг |
Гликозидные производные и их применения
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
US9056850B2
(en)
*
|
2008-10-17 |
2015-06-16 |
Janssen Pharmaceutica N.V. |
Process for the preparation of compounds useful as inhibitors of SGLT
|
WO2010045656A2
(en)
*
|
2008-10-17 |
2010-04-22 |
Nectid, Inc. |
Novel sglt2 inhibitor dosage forms
|
JP2012512848A
(ja)
|
2008-12-23 |
2012-06-07 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
有機化合物の塩の形態
|
AR074990A1
(es)
|
2009-01-07 |
2011-03-02 |
Boehringer Ingelheim Int |
Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
|
PL2395983T3
(pl)
|
2009-02-13 |
2020-09-07 |
Boehringer Ingelheim International Gmbh |
Kompozycja farmaceutyczna zawierająca inhibitor sglt2, inhibitor dpp-iv i ewentualnie dalszy środek przeciwcukrzycowy oraz jej zastosowania
|
SG10201600204YA
(en)
|
2009-02-13 |
2016-02-26 |
Boehringer Ingelheim Int |
SGLT-2 Inhibitor For Treating Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus, Impaired Glucose Tolerance Or Hyperglycemia
|
UY32427A
(es)
|
2009-02-13 |
2010-09-30 |
Boheringer Ingelheim Internat Gmbh |
Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
|
AP2011005780A0
(en)
|
2009-02-13 |
2011-08-31 |
Boehringer Ingelheim Int |
Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient.
|
AR075582A1
(es)
*
|
2009-02-23 |
2011-04-20 |
Taisho Pharmaceutical Co Ltd |
Compuestos de 4- isopropilfenilglucitol
|
EP2226076A1
(de)
|
2009-02-25 |
2010-09-08 |
Henning Vollert |
Pflanzlicher Extrakt zur Prophylaxe und Behandlung von hyperglykämischen Erkrankungen
|
CA2757231A1
(en)
*
|
2009-03-31 |
2010-10-07 |
Boehringer Ingelheim International Gmbh |
1-heterocyclyl-1,5-dihydro-pyrazolo [3,4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
|
WO2010138535A1
(en)
*
|
2009-05-27 |
2010-12-02 |
Bristol-Myers Squibb Company |
Methods for treating type 2 diabetes in patients resistant to previous treatment with other anti-diabetic drugs employing an sglt2 inhibitor and compositions thereof
|
US20110009347A1
(en)
|
2009-07-08 |
2011-01-13 |
Yin Liang |
Combination therapy for the treatment of diabetes
|
ES2416459T3
(es)
|
2009-07-10 |
2013-08-01 |
Janssen Pharmaceutica, N.V. |
Procedimiento de cristalización para 1-( -D-glucopiranosil)-4-metil-3-[5-(4-fluorofenil)-2-tienilmetil]benceno
|
TW201118099A
(en)
*
|
2009-08-12 |
2011-06-01 |
Boehringer Ingelheim Int |
New compounds for the treatment of CNS disorders
|
KR101811997B1
(ko)
*
|
2009-09-30 |
2017-12-26 |
베링거 인겔하임 인터내셔날 게엠베하 |
1클로로4(베타d글루코피라노스1일)2(4((s)테트라하이드로푸란3일옥시)벤질)벤젠의 결정형의 제조방법
|
IN2012DN02751A
(nl)
*
|
2009-09-30 |
2015-09-18 |
Boehringer Ingelheim Int |
|
US10610489B2
(en)
|
2009-10-02 |
2020-04-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
|
DK2488515T3
(en)
*
|
2009-10-14 |
2017-02-27 |
Janssen Pharmaceutica Nv |
PROCEDURE FOR THE PREPARATION OF COMPOUNDS USED AS INHIBITORS OF SGLT2
|
US8163704B2
(en)
*
|
2009-10-20 |
2012-04-24 |
Novartis Ag |
Glycoside derivatives and uses thereof
|
NZ599945A
(en)
|
2009-11-02 |
2014-05-30 |
Pfizer |
Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
|
PL2498759T3
(pl)
|
2009-11-13 |
2019-03-29 |
Astrazeneca Ab |
Formulacje tabletek o natychmiastowym uwalnianiu
|
PT2498758T
(pt)
*
|
2009-11-13 |
2018-10-23 |
Astrazeneca Uk Ltd |
Formulações de comprimido bicamada
|
US8765728B2
(en)
|
2009-11-16 |
2014-07-01 |
Mellitech |
[1,5]-diazocin derivatives
|
JP2013512229A
(ja)
|
2009-11-27 |
2013-04-11 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
遺伝子型が同定された糖尿病患者のリナグリプチン等のddp−iv阻害薬による治療
|
WO2011070592A2
(en)
|
2009-12-09 |
2011-06-16 |
Panacea Biotec Ltd. |
Novel sugar derivatives
|
CN102134226B
(zh)
*
|
2010-01-26 |
2013-06-12 |
天津药物研究院 |
一类苯基c-葡萄糖苷衍生物、其制备方法和用途
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
WO2011120923A1
(en)
|
2010-03-30 |
2011-10-06 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
|
BR112012028136A2
(pt)
|
2010-05-05 |
2016-08-09 |
Boehringer Ingelheim Int |
terapia de combinaçao
|
JP5596799B2
(ja)
|
2010-05-11 |
2014-09-24 |
田辺三菱製薬株式会社 |
カナグリフロジン含有錠剤
|
ES2596291T3
(es)
|
2010-05-11 |
2017-01-05 |
Janssen Pharmaceutica, N.V. |
Formulaciones farmacéuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienilmetilbenceno como inhibidores de sglt
|
WO2011153712A1
(en)
|
2010-06-12 |
2011-12-15 |
Theracos, Inc. |
Crystalline form of benzylbenzene sglt2 inhibitor
|
EP3725325B1
(en)
|
2010-06-24 |
2023-05-31 |
Boehringer Ingelheim International GmbH |
Diabetes therapy
|
PL2603511T3
(pl)
|
2010-08-12 |
2017-08-31 |
Boehringer Ingelheim Int |
Pochodne 6-cykloalkilo-1,5-dihydropirazolo[3,4-d]pirymidyn-4-onu i ich zastosowanie jako inhibitorów PDE9A
|
WO2012025857A1
(en)
|
2010-08-23 |
2012-03-01 |
Hetero Research Foundation |
Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors
|
WO2012031124A2
(en)
|
2010-09-03 |
2012-03-08 |
Bristol-Myers Squibb Company |
Drug formulations using water soluble antioxidants
|
WO2012037034A1
(en)
|
2010-09-14 |
2012-03-22 |
Glycomimetics, Inc. |
E-selectin antagonists
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
WO2012041898A1
(en)
|
2010-09-29 |
2012-04-05 |
Celon Pharma Sp. Z O.O. |
Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
|
CN102453026A
(zh)
|
2010-10-27 |
2012-05-16 |
上海艾力斯医药科技有限公司 |
C-芳基葡糖苷衍生物、制备方法及其应用
|
US20120283169A1
(en)
|
2010-11-08 |
2012-11-08 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
TWI631963B
(zh)
*
|
2011-01-05 |
2018-08-11 |
雷西肯製藥股份有限公司 |
包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法
|
EP2670397B1
(en)
|
2011-02-01 |
2020-05-13 |
Bristol-Myers Squibb Company |
Pharmaceutical formulations including an amine compound
|
US20130035281A1
(en)
*
|
2011-02-09 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US8809345B2
(en)
|
2011-02-15 |
2014-08-19 |
Boehringer Ingelheim International Gmbh |
6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
|
CN102643256B
(zh)
*
|
2011-02-18 |
2014-12-24 |
上海璎黎科技有限公司 |
一种芳基糖苷类化合物及其制备方法和应用
|
AR085689A1
(es)
|
2011-03-07 |
2013-10-23 |
Boehringer Ingelheim Int |
Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
|
CN102167715B
(zh)
*
|
2011-03-07 |
2013-04-24 |
上海惠斯生物科技有限公司 |
一种钠-葡萄糖协同运转蛋白-2原料药的共晶制备方法
|
PT2697218T
(pt)
|
2011-04-13 |
2016-07-13 |
Janssen Pharmaceutica Nv |
Processo para preparação de compostos úteis como inibidores da sglt2
|
CN102757415B
(zh)
*
|
2011-04-25 |
2015-07-29 |
北京普禄德医药科技有限公司 |
一种钠依赖性葡萄糖转运蛋白抑制剂及其制备方法和用途
|
US9035044B2
(en)
|
2011-05-09 |
2015-05-19 |
Janssen Pharmaceutica Nv |
L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
|
US9434670B2
(en)
*
|
2011-05-26 |
2016-09-06 |
Tfchem |
Family of aryl, heteroaryl, O-aryl and O-heteroaryl carbasugars
|
ES2448398T3
(es)
|
2011-06-03 |
2014-03-13 |
Ratiopharm Gmbh |
Composición farmacéutica que comprende dapagliflozina y ciclodextrina
|
JP5835598B2
(ja)
|
2011-06-03 |
2015-12-24 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
神経弛緩剤で治療されている患者において代謝性障害を治療するためのsglt−2阻害剤
|
US9480755B2
(en)
*
|
2011-06-03 |
2016-11-01 |
Ratiopharm Gmbh |
Pharmaceutical composition comprising dapagliflozin and cyclodextrin
|
KR101719758B1
(ko)
|
2011-06-25 |
2017-03-24 |
수안주 파마 코포레이션 리미티드 |
씨 글루코사이드 유도체
|
US20130035298A1
(en)
|
2011-07-08 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
CN103781788B
(zh)
|
2011-07-15 |
2016-08-17 |
勃林格殷格翰国际有限公司 |
经取代的喹唑啉、其制备及其在药物组合物中的用途
|
JP2014530186A
(ja)
|
2011-09-13 |
2014-11-17 |
パナセア バイオテック リミテッド |
新規sglt阻害剤
|
JP2014532639A
(ja)
*
|
2011-10-31 |
2014-12-08 |
サイノファーム タイワン,リミティド |
Sglt2阻害剤の結晶および非結晶形態
|
EP2597090A1
(en)
*
|
2011-11-28 |
2013-05-29 |
Sandoz AG |
Crystalline dapagliflozin hydrate
|
JP2015500887A
(ja)
|
2011-12-22 |
2015-01-08 |
グリコミメティクス, インコーポレイテッド |
E−セレクチンアンタゴニスト化合物、組成物および使用方法
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
US9192617B2
(en)
|
2012-03-20 |
2015-11-24 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US9193751B2
(en)
|
2012-04-10 |
2015-11-24 |
Theracos, Inc. |
Process for the preparation of benzylbenzene SGLT2 inhibitors
|
EP3685839A1
(en)
|
2012-05-14 |
2020-07-29 |
Boehringer Ingelheim International GmbH |
Linagliptin for use in the treatment of albuminuria and kidney related diseases
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
WO2013178064A1
(zh)
*
|
2012-05-29 |
2013-12-05 |
广东东阳光药业有限公司 |
吡喃葡萄糖基衍生物、其制备方法及其在医药上的应用
|
EP2679229B1
(de)
|
2012-06-30 |
2019-02-27 |
BioActive Food GmbH |
Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen
|
JP6198013B2
(ja)
*
|
2012-08-30 |
2017-09-20 |
大正製薬株式会社 |
Sglt2阻害薬と抗高血圧薬との組み合わせ
|
AU2013355238B2
(en)
|
2012-12-07 |
2017-12-14 |
Glycomimetics, Inc. |
Compounds, compositions and methods using E-selectin antagonists for mobilization of hematopoietic cells
|
CN103910769B
(zh)
|
2012-12-31 |
2018-10-02 |
上海璎黎药业有限公司 |
葡萄糖衍生物和脯氨酸的复合物、晶体、制备方法及应用
|
EP2774619B1
(de)
|
2013-03-04 |
2016-05-18 |
BioActive Food GmbH |
Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen
|
US8652527B1
(en)
|
2013-03-13 |
2014-02-18 |
Upsher-Smith Laboratories, Inc |
Extended-release topiramate capsules
|
EP2968375B1
(en)
|
2013-03-14 |
2019-06-12 |
MSD International GmbH |
Methods for preparing sglt2 inhibitors
|
CA2905435A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
EP2970384A1
(en)
|
2013-03-15 |
2016-01-20 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
US9101545B2
(en)
|
2013-03-15 |
2015-08-11 |
Upsher-Smith Laboratories, Inc. |
Extended-release topiramate capsules
|
EP4245765A3
(en)
|
2013-04-04 |
2024-03-20 |
Boehringer Ingelheim Vetmedica GmbH |
Treatment of metabolic disorders in equine animals
|
ES2702174T3
(es)
|
2013-04-05 |
2019-02-27 |
Boehringer Ingelheim Int |
Usos terapéuticos de empagliflozina
|
US11813275B2
(en)
|
2013-04-05 |
2023-11-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US20140303097A1
(en)
|
2013-04-05 |
2014-10-09 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
PT2986304T
(pt)
|
2013-04-18 |
2022-02-25 |
Boehringer Ingelheim Int |
Composição farmacêutica, métodos para o tratamento e suas utilizações
|
EP2991999B1
(en)
|
2013-04-29 |
2019-05-08 |
Mapi Pharma Limited |
Dapagliflozin lactose co-crystal
|
BR112015030326A2
(pt)
|
2013-06-05 |
2017-08-29 |
Synergy Pharmaceuticals Inc |
Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
|
WO2015040571A1
(en)
|
2013-09-23 |
2015-03-26 |
Ranbaxy Laboratories Limited |
Process for the preparation of dapagliflozin
|
US9394329B2
(en)
|
2013-09-27 |
2016-07-19 |
Sunshine Lake Pharma Co., Ltd. |
Glucopyranosyl derivatives and their uses in medicine
|
US20160237054A1
(en)
*
|
2013-09-27 |
2016-08-18 |
Sun Pharmaceutical Industries Limited |
Process for the purification of dapagliflozin
|
WO2015051484A1
(en)
|
2013-10-12 |
2015-04-16 |
Theracos, Inc. |
Preparation of hydroxy-benzylbenzene derivatives
|
WO2015063726A1
(en)
|
2013-10-31 |
2015-05-07 |
Ranbaxy Laboratories Limited |
Process for the preparation of 4-bromo-1-chloro-2-(4-ethoxybenzyl)benzene
|
DK3082829T3
(da)
|
2013-12-17 |
2021-05-03 |
Boehringer Ingelheim Vetmedica Gmbh |
Sglt2-inhibitorer til behandlingen af metaboliske lidelser i kattedyr
|
US9902751B2
(en)
|
2013-12-30 |
2018-02-27 |
Mylan Laboratories Limited |
Process for the preparation of empagliflozin
|
US9315438B2
(en)
|
2014-01-03 |
2016-04-19 |
Xuanzhu Pharma Co., Ltd |
Optically pure benzyl-4-chlorophenyl-C-glucoside derivative
|
CN106349201B
(zh)
*
|
2014-01-03 |
2018-09-18 |
山东轩竹医药科技有限公司 |
光学纯的苄基-4-氯苯基的c-糖苷衍生物
|
CN103739581B
(zh)
*
|
2014-01-23 |
2016-11-23 |
中国药科大学 |
C-芳基葡萄糖苷sglt2抑制剂
|
DK3096765T3
(en)
|
2014-01-23 |
2019-03-04 |
Boehringer Ingelheim Vetmedica Gmbh |
Treatment of metabolic disorders in dogs
|
CN104829572B
(zh)
*
|
2014-02-10 |
2019-01-04 |
江苏豪森药业集团有限公司 |
达格列净新晶型及其制备方法
|
IN2014MU00626A
(nl)
*
|
2014-02-21 |
2015-09-25 |
Cadila Healthcare Ltd |
|
EP3110449B1
(en)
|
2014-02-28 |
2023-06-28 |
Boehringer Ingelheim International GmbH |
Medical use of a dpp-4 inhibitor
|
WO2015128853A1
(en)
|
2014-02-28 |
2015-09-03 |
Sun Pharmaceutical Industries Limited |
Dapagliflozin compositions
|
US20170029398A1
(en)
*
|
2014-03-06 |
2017-02-02 |
Srinivasan Thirumalai Rajan |
Process for the preparation of (1s)-1,5-anhydro-1-c-{4-chloro-3-4[(4-ethoxyphenyl)methyl]phenyl]-glucitol and its solvate thereof
|
ES2811261T3
(es)
|
2014-04-01 |
2021-03-11 |
Boehringer Ingelheim Vetmedica Gmbh |
Tratamiento de trastornos metabólicos en animales equinos
|
CN105001213B
(zh)
*
|
2014-04-14 |
2020-08-28 |
上海迪诺医药科技有限公司 |
C-芳基糖苷衍生物、其药物组合物、制备方法及应用
|
EP2944311A1
(de)
|
2014-05-16 |
2015-11-18 |
BioActive Food GmbH |
Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen
|
JP2017515908A
(ja)
*
|
2014-05-16 |
2017-06-15 |
アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag |
Sglt2インヒビター誘発性グルカゴン分泌の抑制方法
|
WO2015198227A1
(en)
|
2014-06-23 |
2015-12-30 |
Sun Pharmaceutical Industries Limited |
Co-crystal of dapagliflozin with citric acid
|
US9757404B2
(en)
|
2014-09-25 |
2017-09-12 |
Astrazeneca Ab |
Combination comprising an omega-3 fatty acid composition and an SGLT2 inhibitor
|
CN104327027B
(zh)
*
|
2014-10-14 |
2017-04-05 |
中国药科大学 |
一类新型c‑芳基葡萄糖苷sglt2抑制剂
|
CN104478839A
(zh)
*
|
2014-11-24 |
2015-04-01 |
苏州乔纳森新材料科技有限公司 |
一种达格列净的合成方法
|
CN104496952B
(zh)
*
|
2014-11-28 |
2017-04-19 |
深圳翰宇药业股份有限公司 |
一种达格列净的合成方法
|
SI3227310T1
(sl)
|
2014-12-03 |
2019-11-29 |
Glycomimetics Inc |
Heterobifunkcionalni inhibitorji e-selektinov in receptorjev kemokina CXCR4
|
CN105753910A
(zh)
*
|
2014-12-16 |
2016-07-13 |
康普药业股份有限公司 |
一种卡格列净中间体的制备方法
|
CN104529970A
(zh)
*
|
2015-01-08 |
2015-04-22 |
江苏联环药业股份有限公司 |
制备达格列净的方法
|
CN104530149A
(zh)
*
|
2015-01-14 |
2015-04-22 |
佛山市赛维斯医药科技有限公司 |
卤代苯基双o-葡萄糖苷衍生物、其制备方法和用途
|
CN104478959A
(zh)
*
|
2015-01-14 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
含腈基联苯双葡萄糖苷结构化合物、其制备方法和用途
|
CN104478966A
(zh)
*
|
2015-01-14 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
含苯胺噻唑基的o-半乳糖苷衍生物、其制备方法和用途
|
CN104478957A
(zh)
*
|
2015-01-14 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
一种含腈基苯和双o-葡萄糖苷衍生物、其制备方法和用途
|
CN104478968A
(zh)
*
|
2015-01-14 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
含噻唑基的o-半乳糖苷衍生物、其制备方法和用途
|
CN104497070A
(zh)
*
|
2015-01-15 |
2015-04-08 |
佛山市赛维斯医药科技有限公司 |
一种含三氟甲基苯s-葡萄糖苷结构的化合物和用途
|
CN104478963A
(zh)
*
|
2015-01-15 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
一种含腈基苯s-葡萄糖苷结构的化合物及其用途
|
CN104478965A
(zh)
*
|
2015-01-15 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
一类烷氧基苯基s-葡萄糖苷衍生物、其制备方法和用途
|
EP3256482B1
(en)
|
2015-02-09 |
2019-11-27 |
Indoco Remedies Limited |
Process for the preparation of sglt inhibitor compounds
|
EA201791982A1
(ru)
|
2015-03-09 |
2020-02-17 |
Интекрин Терапьютикс, Инк. |
Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
|
WO2016161995A1
(en)
|
2015-04-08 |
2016-10-13 |
Zentiva, K.S. |
Solid forms of amorphous dapagliflozin
|
US10556877B2
(en)
|
2015-05-05 |
2020-02-11 |
Glenmark Life Sciences Limited |
Process for preparation of dapagliflozin
|
CN106317068A
(zh)
*
|
2015-06-23 |
2017-01-11 |
中国科学院上海药物研究所 |
一种c,o-螺环芳基糖苷类化合物及其制备和应用
|
CN104961715B
(zh)
*
|
2015-07-10 |
2017-08-22 |
浙江美诺华药物化学有限公司 |
一种达格列净的制备方法
|
US20170071970A1
(en)
|
2015-09-15 |
2017-03-16 |
Janssen Pharmaceutica Nv |
Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
|
WO2017046730A1
(en)
|
2015-09-15 |
2017-03-23 |
Laurus Labs Private Limited |
Co-crystals of sglt2 inhibitors, process for their preparation and pharmaceutical compositions thereof
|
CZ2015729A3
(cs)
|
2015-10-13 |
2017-04-26 |
Zentiva, K.S. |
Příprava intermediátů pro syntézu Canagliflozinu a Dapagliflozinu
|
CN105218329B
(zh)
*
|
2015-10-15 |
2017-05-03 |
上海应用技术学院 |
一种列净类似物中间体及其制备方法
|
EP3362055B1
(en)
|
2015-10-15 |
2023-01-18 |
Boehringer Ingelheim International GmbH |
Sglt-2 inhibitor for use in the treatment of a metabolic myopathy
|
US9845303B2
(en)
|
2015-10-19 |
2017-12-19 |
Cadila Healthcare Limited |
Process for the preparation of dapagliflozin
|
CN106892929B
(zh)
*
|
2015-12-17 |
2020-01-14 |
上海艾力斯医药科技有限公司 |
螺缩酮衍生物及其制备方法和应用
|
CN105693669A
(zh)
*
|
2015-12-28 |
2016-06-22 |
南昌大学 |
一种抗糖尿病化合物及其制备方法和用途
|
US10752604B2
(en)
*
|
2016-01-04 |
2020-08-25 |
Je II Pharmaceutical Co., Ltd. |
C-glucoside derivative containing fused phenyl ring or pharmaceutically acceptable salt thereof, process for preparing same, and pharmaceutical composition comprising same
|
WO2017118945A1
(en)
|
2016-01-08 |
2017-07-13 |
Lupin Limited |
Premix of dapagliflozin and process for the preparation thereof
|
CA3009836A1
(en)
|
2016-01-22 |
2017-07-27 |
Glycomimetics, Inc. |
Glycomimetic inhibitors of pa-il and pa-iil lectins
|
US9834533B2
(en)
*
|
2016-02-19 |
2017-12-05 |
Scinopharm Taiwan, Ltd. |
Process for preparing SGLT2 inhibitors and intermediates thereof
|
US11291678B2
(en)
|
2016-03-02 |
2022-04-05 |
Glycomimetics, Inc |
Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin
|
MX2018011696A
(es)
|
2016-03-31 |
2019-06-06 |
Lupin Ltd |
Composición farmacéutica de dapagliflozina.
|
CN107304194A
(zh)
*
|
2016-04-20 |
2017-10-31 |
扬子江药业集团上海海尼药业有限公司 |
制备达格列净的方法
|
US10464915B2
(en)
*
|
2016-05-24 |
2019-11-05 |
Jiangsu Hansoh Pharmaceutical Group Co., Ltd. |
Dapagliflozin crystal form and preparation method and use thereof
|
WO2017203229A1
(en)
|
2016-05-27 |
2017-11-30 |
Cipla Limited |
Dapagliflozin premixes
|
MX2018015089A
(es)
|
2016-06-10 |
2019-05-13 |
Boehringer Ingelheim Int |
Combinacion de linagliptina y metformina.
|
WO2018002673A1
(en)
|
2016-07-01 |
2018-01-04 |
N4 Pharma Uk Limited |
Novel formulations of angiotensin ii receptor antagonists
|
WO2018031445A1
(en)
|
2016-08-08 |
2018-02-15 |
Glycomimetics, Inc. |
Combination of t-cell checkpoint inhibitors with inhibitors of e-selectin or cxcr4, or with heterobifunctional inhibitors of both e-selectin and cxcr4
|
EP3497090B1
(en)
*
|
2016-08-09 |
2022-08-03 |
Laurus Labs Limited |
Novel processes for preparation of dapagliflozin or its solvates or co-crystals thereof
|
WO2018029264A1
(en)
|
2016-08-10 |
2018-02-15 |
Amneal Pharmaceuticals Company Gmbh |
Process for preparation of dapagliflozin and intermediates thereof
|
JP7069136B2
(ja)
|
2016-10-07 |
2022-05-17 |
グリコミメティクス, インコーポレイテッド |
極めて強力な多量体e-セレクチンアンタゴニスト
|
JP2019531320A
(ja)
|
2016-10-19 |
2019-10-31 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ssao/vap−1阻害剤とsglt2阻害剤とを含む組合せ、その使用
|
KR20180058510A
(ko)
|
2016-11-24 |
2018-06-01 |
한미약품 주식회사 |
다파글리플로진 l-프롤린을 포함하는 약제학적 제제
|
CN108218928B
(zh)
*
|
2016-12-13 |
2020-06-30 |
华润双鹤药业股份有限公司 |
葡萄糖苷的二环衍生物及其制备方法和用途
|
WO2018142422A1
(en)
*
|
2017-02-02 |
2018-08-09 |
Indoco Remedies Limited |
Process for the preparation of dapagliflozin
|
EP3596096A1
(en)
|
2017-03-15 |
2020-01-22 |
GlycoMimetics, Inc. |
Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
|
US11020412B2
(en)
|
2017-03-16 |
2021-06-01 |
Inventia Healthcare Limited |
Pharmaceutical composition comprising dapagliflozin
|
EP3606527A1
(en)
|
2017-04-03 |
2020-02-12 |
Coherus Biosciences, Inc. |
Ppar-gamma agonist for treatment of progressive supranuclear palsy
|
US11312740B2
(en)
|
2017-05-09 |
2022-04-26 |
Piramal Pharma Limited |
Process for the preparation of SGLT2 inhibitors and intermediates thereof
|
TWI797133B
(zh)
|
2017-06-09 |
2023-04-01 |
丹麥商諾佛 儂迪克股份有限公司 |
用於經口投予的固體組成物
|
KR101943382B1
(ko)
|
2017-09-19 |
2019-01-29 |
오토텔릭바이오 주식회사 |
Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물
|
JP7275131B2
(ja)
|
2017-11-30 |
2023-05-17 |
グリコミメティクス, インコーポレイテッド |
骨髄浸潤リンパ球を動員する方法、およびその使用
|
CN111566117A
(zh)
|
2017-12-29 |
2020-08-21 |
糖模拟物有限公司 |
E-选择蛋白和半乳凝素-3的异双功能抑制剂
|
JP7455064B2
(ja)
|
2018-03-05 |
2024-03-25 |
グリコミメティクス, インコーポレイテッド |
急性骨髄性白血病および関連状態を処置する方法
|
WO2019201752A1
(en)
|
2018-04-17 |
2019-10-24 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
KR102204439B1
(ko)
|
2018-05-14 |
2021-01-18 |
에이치케이이노엔 주식회사 |
Sglt-2 억제제 및 dpp-iv 억제제를 포함하는 약제학적 조성물
|
EP3810623A1
(en)
|
2018-06-25 |
2021-04-28 |
Pharmathen S.A. |
A novel process for the preparation of sglt-2 inhibitors
|
KR20200005320A
(ko)
|
2018-07-06 |
2020-01-15 |
한미약품 주식회사 |
무정형의 다파글리플로진 l-프롤린을 포함하는 약학적 제제 및 이의 제조방법
|
PE20210644A1
(es)
*
|
2018-07-19 |
2021-03-23 |
Astrazeneca Ab |
METODOS DE TRATAMIENTO DE HFpEF EMPLEANDO DAPAGLIFLOZINA Y COMPOSICIONES QUE COMPRENDEN LA MISMA
|
WO2020039394A1
(en)
|
2018-08-24 |
2020-02-27 |
Novartis Ag |
New drug combinations
|
KR102131359B1
(ko)
|
2018-09-07 |
2020-07-07 |
오토텔릭바이오 주식회사 |
안정성이 향상된 의약 조성물
|
CN109705075B
(zh)
*
|
2018-12-13 |
2022-12-23 |
苏中药业集团股份有限公司 |
一种达格列净的纯化方法
|
WO2020139962A1
(en)
|
2018-12-27 |
2020-07-02 |
Glycomimetics, Inc. |
Heterobifunctional inhibitors of e-selectin and galectin-3
|
JP2022530575A
(ja)
|
2019-08-30 |
2022-06-30 |
アストラゼネカ・アクチエボラーグ |
ダパグリフロジンを用いて、駆出率が低下した心不全を治療する方法
|
BR112022010385A2
(pt)
*
|
2019-11-28 |
2022-08-23 |
Boehringer Ingelheim Vetmedica Gmbh |
Uso de inibidores de sglt-2 na secagem de mamíferos não humanos
|
EP4106744A1
(en)
|
2020-02-17 |
2022-12-28 |
Boehringer Ingelheim Vetmedica GmbH |
Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in felines
|
EP4106732A1
(en)
|
2020-02-21 |
2022-12-28 |
Zaklady Farmaceutyczne Polpharma S.A. |
Pharmaceutical composition comprising dapagliflozin
|
WO2021176096A1
(en)
|
2020-03-05 |
2021-09-10 |
Krka, D.D., Novo Mesto |
Pharmaceutical composition comprising sglt2 inhibitor
|
AU2021230562A1
(en)
|
2020-03-06 |
2022-09-22 |
Vertex Pharmaceuticals Incorporated |
Methods of treating APOL-1 dependent focal segmental glomerulosclerosis
|
CN115916197A
(zh)
|
2020-04-22 |
2023-04-04 |
拜耳公司 |
用于治疗和/或预防心血管和/或肾脏疾病的非奈利酮和sglt2抑制剂的组合
|
US20230165856A1
(en)
|
2020-04-29 |
2023-06-01 |
Astrazeneca Ab |
Dapagliflozin and ambrisentan for the prevention and treatment of covid-19
|
CN115867538A
(zh)
|
2020-06-05 |
2023-03-28 |
新梅斯托克公司 |
高纯的无定形达格列净的制备
|
WO2021260617A1
(en)
*
|
2020-06-25 |
2021-12-30 |
Hikal Limited |
An improved process for preparation of dapagliflozin propanediol monohydrate
|
JP2023541766A
(ja)
|
2020-07-10 |
2023-10-04 |
アストラゼネカ・アクチエボラーグ |
慢性腎疾患の治療のためのジボテンタン及びダパグリフロジンの組み合わせ
|
WO2022022865A1
(en)
|
2020-07-27 |
2022-02-03 |
Astrazeneca Ab |
Methods of treating chronic kidney disease with dapagliflozin
|
WO2022051316A1
(en)
|
2020-09-03 |
2022-03-10 |
Coherus Biosciences, Inc. |
Fixed dose combinations of chs-131 and a sglt-2 inhibitor
|
EP4206212A4
(en)
|
2020-09-30 |
2024-05-22 |
Beijing Creatron Institute of Pharmaceutical Research Co., Ltd. |
SGLT-2 AND SARCOSINE INHIBITOR COCRYSTAL, PROCESS FOR PREPARATION THEREFOR AND USE THEREOF
|
TR202019590A2
(tr)
|
2020-12-03 |
2022-06-21 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Dapagli̇flozi̇n ve metformi̇n hi̇droklorür formülasyonlarina yöneli̇k bi̇r proses
|
TR202019589A2
(tr)
|
2020-12-03 |
2022-06-21 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Dapagli̇flozi̇n ve metformi̇n hi̇droklorür i̇çeren fi̇lm kapli tablet formülasyonu
|
TR202019592A2
(tr)
|
2020-12-03 |
2022-06-21 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Amorf dapagliflozinin katı farmasötik formülasyonları
|
WO2022119543A1
(en)
|
2020-12-03 |
2022-06-09 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
A process for tablet formulations comprising amorphous dapagliflozin and metformin hydrochloride
|
US20240212818A1
(en)
|
2021-04-01 |
2024-06-27 |
Astrazeneca Uk Limited |
Systems and methods for managing prediabetes with a gliflozin sodiumglucose cotransport 2 inhibitor pharmaceutical composition
|
EP4079296A1
(en)
|
2021-04-21 |
2022-10-26 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
A bilayer tablet formulation comprising amorphous dapagliflozin and metformin
|
CN117715639A
(zh)
|
2021-07-28 |
2024-03-15 |
勃林格殷格翰动物保健有限公司 |
Sglt-2抑制剂用于预防和/或治疗非人哺乳动物中的肾脏病的用途
|
EP4376819A1
(en)
|
2021-07-28 |
2024-06-05 |
Boehringer Ingelheim Vetmedica GmbH |
Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
|
KR20240041966A
(ko)
|
2021-07-28 |
2024-04-01 |
베링거잉겔하임베트메디카게엠베하 |
고양이를 제외한 비인간 포유류, 특히 개에서 심장 질환의 예방 및/또는 치료를 위한 sglt-2 억제제의 용도
|
CN113773194B
(zh)
|
2021-08-16 |
2023-05-02 |
浙江奥翔药业股份有限公司 |
作为降糖药合成原料的5-溴-2-氯-苯甲酸的制备方法
|
WO2023129595A1
(en)
|
2021-12-30 |
2023-07-06 |
Newamsterdam Pharma B.V. |
Obicetrapib and sglt2 inhibitor combination
|
EP4212150A1
(en)
|
2022-01-13 |
2023-07-19 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
A bilayer tablet composition comprising amorphous dapagliflozin and metformin
|
WO2023144722A1
(en)
|
2022-01-26 |
2023-08-03 |
Astrazeneca Ab |
Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes
|
WO2023227492A1
(en)
|
2022-05-25 |
2023-11-30 |
Boehringer Ingelheim Vetmedica Gmbh |
Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
|
TW202415364A
(zh)
|
2022-06-07 |
2024-04-16 |
瑞典商阿斯特捷利康公司 |
Rxfp1調節劑和sglt2抑制劑之組合
|
KR102490653B1
(ko)
*
|
2022-08-03 |
2023-01-20 |
진양제약주식회사 |
다파글리플로진 및 글리메피리드를 포함하는 약제학적 조성물
|
KR20240028315A
(ko)
|
2022-08-24 |
2024-03-05 |
주식회사 제뉴원사이언스 |
다파글리플로진, 시타글립틴, 및 메트포르민을 함유하는 복합 제제
|